SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-257884
Filing Date
2020-09-29
Accepted
2020-09-29 16:49:01
Documents
14
Period of Report
2020-09-29
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d42629d8k.htm   iXBRL 8-K 25721
2 EX-99.1 d42629dex991.htm EX-99.1 13521
6 GRAPHIC g42629g0929222323293.jpg GRAPHIC 2893
  Complete submission text file 0001193125-20-257884.txt   171462

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA ctic-20200929.xsd EX-101.SCH 3082
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctic-20200929_lab.xml EX-101.LAB 18139
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctic-20200929_pre.xml EX-101.PRE 11416
7 EXTRACTED XBRL INSTANCE DOCUMENT d42629d8k_htm.xml XML 3450
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28386 | Film No.: 201209455
SIC: 2834 Pharmaceutical Preparations